Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Revolution Medicines (RVMD) Net Cash Flow (2019 - 2025)

Revolution Medicines (RVMD) has 7 years of Net Cash Flow data on record, last reported at $166.3 million in Q4 2025.

  • For Q4 2025, Net Cash Flow fell 51.46% year-over-year to $166.3 million; the TTM value through Dec 2025 reached -$158.2 million, down 3.77%, while the annual FY2025 figure was -$158.2 million, 3.77% down from the prior year.
  • Net Cash Flow reached $166.3 million in Q4 2025 per RVMD's latest filing, up from -$184.1 million in the prior quarter.
  • Across five years, Net Cash Flow topped out at $342.6 million in Q4 2024 and bottomed at -$407.7 million in Q1 2024.
  • Average Net Cash Flow over 5 years is $14.2 million, with a median of -$15.1 million recorded in 2022.
  • The widest YoY moves for Net Cash Flow: up 2554.39% in 2023, down 667.35% in 2023.
  • A 5-year view of Net Cash Flow shows it stood at -$20.0 million in 2021, then increased by 12.37% to -$17.5 million in 2022, then skyrocketed by 2030.45% to $338.4 million in 2023, then increased by 1.25% to $342.6 million in 2024, then tumbled by 51.46% to $166.3 million in 2025.
  • Per Business Quant database, its latest 3 readings for Net Cash Flow were $166.3 million in Q4 2025, -$184.1 million in Q3 2025, and $69.1 million in Q2 2025.